PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25484141-0	2015	Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.	Docetaxel	90-99	androgen receptor	Homo sapiens	14-31	
25484141-2	2015	However, concerns regarding cross-resistance between the taxanes docetaxel and cabazitaxel and these AR-targeted agents have arisen, and the optimal drug treatment sequence is unknown.	Docetaxel	65-74	androgen receptor	Homo sapiens	101-103	
25484141-6	2015	Docetaxel inhibited tumor growth, AR nuclear localization, and AR-regulated gene expression in enzalutamide-naive tumors, but did not in enzalutamide-resistant tumors, demonstrating in vivo cross-resistance.	Docetaxel	0-9	androgen receptor	Homo sapiens	34-36	
25484141-6	2015	Docetaxel inhibited tumor growth, AR nuclear localization, and AR-regulated gene expression in enzalutamide-naive tumors, but did not in enzalutamide-resistant tumors, demonstrating in vivo cross-resistance.	Docetaxel	0-9	androgen receptor	Homo sapiens	63-65	
25484141-8	2015	These findings demonstrate that the AR pathway is able to confer in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in CRPC.	Docetaxel	115-124	androgen receptor	Homo sapiens	36-38